What Is the Link Between Shingles and Cancer?

Shingles and cancer are connected in both directions: people with cancer develop shingles far more often than healthy individuals, and a new shingles episode can sometimes be an early signal of an undiagnosed malignancy. The relationship is rooted in the immune system, which both fights cancer and keeps the virus behind shingles in check. When either cancer itself or its treatments weaken immune defenses, the dormant virus can reawaken. The interplay is more nuanced than a simple cause-and-effect story, though, and the practical implications depend heavily on the type of cancer, the treatment involved, and the patient’s age.

Why Cancer Makes Shingles More Likely

Shingles happens when varicella-zoster virus, the same virus that causes chickenpox, reactivates from nerve cells where it has been lying dormant, sometimes for decades. A healthy immune system normally keeps the virus suppressed. Cancer undermines that immune surveillance in two main ways. First, some cancers directly impair immune-cell function, particularly blood cancers like leukemia and lymphoma that affect the very white blood cells responsible for virus control. Second, most cancer treatments, from conventional chemotherapy to newer targeted therapies, suppress the immune system as a side effect.

A large population-based study found that patients with any previous or current cancer had roughly 1.3 times the odds of developing shingles compared to people without cancer. That overall figure masks a striking split: blood cancers carried about 2.5 times the odds of shingles, while solid-organ cancers had a more modest increase of about 1.2 times the odds.¹ Cancer patients also face a higher risk of complications from shingles, including disseminated infections that spread beyond a single nerve region and involve internal organs.²

Blood Cancers Carry the Highest Risk

The gap between blood cancers and solid tumors is worth understanding because it shapes clinical decisions about prevention. Leukemia and lymphoma directly damage or deplete T cells, the immune cells most critical for keeping varicella-zoster virus dormant. Shingles has long been recognized as occurring more frequently in patients with certain leukemias and lymphomas.³ When researchers looked at 21 specific cancer types, the elevated odds of shingles associated with blood cancers were roughly double those seen with solid tumors.¹

This pattern holds in children as well. A nationwide cohort study of children with cancer found that the shingles rate was about eight to nine times higher than in children without cancer overall. When broken down by cancer type, children with leukemia had the steepest increase, at about 14 times the rate of their healthy peers, followed by lymphoma at roughly eight times and solid tumors at about five times.⁴ The magnitude in teens was even more pronounced, and girls appeared to be at higher risk than boys, though the underlying reasons for these differences are not well understood.

How Cancer Treatments Trigger Shingles

It is not just the cancer itself. The treatments used against it are a major driver of shingles risk. A study of U.S. cancer patients found that both solid-tumor and blood-cancer patients were about three times more likely to develop shingles during periods when they were receiving immunosuppressive medications compared to when they were not on such therapy.⁵ That threefold increase held across both cancer categories, suggesting that the drugs themselves, not just the underlying disease, play a central role.

The range of treatments implicated keeps growing. Traditional chemotherapy has long been associated with shingles, but newer agents carry their own risks. Proteasome inhibitors used for multiple myeloma, for instance, prompted the routine addition of antiviral prophylaxis after shingles rates among patients on bortezomib proved unacceptably high.⁶ Emerging therapies like CAR T-cell treatment and bispecific antibodies have led clinicians to incorporate antiviral prophylaxis into treatment protocols, although the ideal duration of preventive dosing remains unclear.⁷

Radiation and the Nerve Factor

Radiation therapy introduces a separate, somewhat mysterious risk. Reports have long noted that shingles tends to appear in or near the area where radiation was delivered.⁸ A study of 120 patients who developed shingles after radiation therapy found that the rash appeared within the radiation field significantly more often than would be expected by chance alone.⁹

The reasons are still being worked out. One case report described a patient with Ewing sarcoma who developed shingles after just a single fraction of radiation directed near the spinal cord, where the virus tends to lie dormant. The authors proposed that radiation aimed near nerve roots where the virus hides could lower the threshold for reactivation through a mechanism potentially distinct from general immune suppression, perhaps involving local nerve damage or inflammatory signals.¹⁰ In a population-level analysis, patients with oral cavity cancer who received radiation therapy had a significantly higher risk of developing shingles compared to matched controls.¹¹ The practical takeaway for patients undergoing radiation is that a painful, blistering rash developing in the treated area warrants prompt evaluation. Early antiviral treatment for shingles works best when started within 72 hours of the rash appearing.

Can Shingles Be an Early Warning Sign of Cancer?

This is the question that probably generates the most anxiety, and it deserves a careful answer. Several large studies have found that people newly diagnosed with shingles face a modestly higher risk of being diagnosed with cancer in the months and years that follow, compared to people who never had shingles. A primary-care database study found that the overall risk of a subsequent cancer diagnosis was roughly 2.4 times higher after a shingles episode, with younger patients showing the strongest association.¹²

A large Canadian study found a similar pattern, with the highest risk concentrated in the first 180 days after shingles. After that initial window, the risk gradually declined but remained statistically elevated for up to five years.¹³ More recently, a cohort study in older adults found an even sharper difference in the first year: about 2.5 percent of adults with shingles received a new cancer diagnosis within 12 months, compared to 0.4 percent of controls, leading the authors to suggest that shingles could serve as a clinical marker of hidden cancer in adults aged 65 to 84.¹⁴

The leading explanation is not that shingles causes cancer, but that a cancer already growing silently can weaken the immune system enough for the dormant virus to reactivate before the cancer itself produces obvious symptoms. In other words, the shingles outbreak may be the first visible sign that something else has gone wrong with immune defenses.

Should a Shingles Diagnosis Prompt Cancer Screening?

Given the statistical link, it is reasonable to wonder whether anyone who gets shingles should be screened for cancer. The evidence is not strong enough to support that step. A systematic review and meta-analysis concluded that while there is an association between shingles and occult cancer, the absolute risk of cancer remains low enough to limit the clinical usefulness of routine screening triggered by a shingles diagnosis alone.¹⁵

What this means practically is that a single episode of shingles in an otherwise healthy 55-year-old is not, by itself, a reason to undergo a full-body cancer workup. You should stay current with age-appropriate cancer screenings regardless, and your doctor may pay closer attention if you have other risk factors or unusual features, such as recurrent shingles episodes, shingles that spreads beyond a single nerve region, or shingles in an unusually young person with no clear explanation. Those atypical presentations are more concerning and may warrant further investigation.

Vaccination for People With Cancer

The recombinant zoster vaccine, which uses a piece of the virus’s protein rather than a live virus, has changed the picture for cancer patients. The older live-virus vaccine was off-limits for anyone with a compromised immune system because a weakened but living virus could cause the very disease it was meant to prevent. The newer vaccine does not carry that risk.

A meta-analysis of the recombinant vaccine in people with weakened immune systems, including cancer patients, found that it reduced shingles cases by about 81 percent compared to placebo. The vaccine prompted measurable increases in both antibody and cellular immune responses. It did cause more injection-site reactions and systemic symptoms like fatigue and muscle aches, but there was no difference in serious side effects or deaths between the vaccinated and placebo groups.¹⁶ It is worth noting that transplant recipients and people with a history of cancer showed somewhat lower immune responses to the vaccine than other immunocompromised groups, so the protection, while real, may not be as robust as in healthy adults.

Real-world vaccination efforts in oncology clinics are growing. One in-house initiative at an oncology clinic vaccinated 200 patients over 14 months, most of whom had metastatic disease and were actively receiving systemic treatment. The adverse reaction reporting rate was low, at about 4.5 percent of doses, with injection-site soreness being the most common complaint. No shingles cases were detected among vaccinated patients during the study period.¹⁷ The timing of vaccination relative to chemotherapy cycles can be coordinated, and many oncology teams now administer the vaccine shortly before or after infusion sessions.

Antiviral Prophylaxis During High-Risk Treatments

For patients on treatments known to carry a high shingles risk, daily antiviral medication is a standard preventive measure. Acyclovir and its relatives have been shown to effectively prevent shingles reactivation in multiple myeloma patients on bortezomib therapy.⁶ This prophylaxis has become a cornerstone of care for intermediate-risk regimens, including myeloma therapies and patients undergoing autologous stem-cell transplants. Newer immunotherapies like CAR T-cell therapy have prompted oncologists to build antiviral prophylaxis into treatment protocols from the start, though the optimal duration of preventive dosing for these newer treatments is still being studied.⁷

If you are undergoing cancer treatment and are not on antiviral prophylaxis, it is worth asking your oncologist whether it would be appropriate, particularly if your regimen involves drugs known to heavily suppress T-cell function. The medication is inexpensive, generally well tolerated, and prevents an episode that can be extremely painful and disruptive to treatment schedules.

When a Rash Looks Like Shingles but Isn’t

A diagnostic trap exists on the other side of the relationship. In rare cases, cancer spreading to the skin can produce a rash that closely mimics the appearance of shingles, complete with blistering lesions that follow a nerve-like strip on one side of the body. Clinicians have a term for this pattern: zosteriform metastasis. A case report described a patient with metastatic colon cancer whose persistent strip-like blistering rash was initially treated as shingles. A skin biopsy eventually revealed malignant cells, not viral infection.¹⁸ Skin metastases from lung cancer can follow the same misleading pattern.¹⁹

The red flags that should prompt a closer look include a “shingles” rash that does not respond to antiviral treatment, one that persists or worsens beyond the typical two-to-four-week course, or one that recurs in exactly the same location. In a cancer patient, any atypical rash deserves a biopsy rather than empirical treatment alone. Mistaking a skin metastasis for shingles delays recognition that the cancer has spread, while mistaking shingles for something else delays antiviral therapy that works best when started early.

Shingles in Children and Young Adults With Cancer

Shingles is relatively rare in healthy children, which is part of why a shingles diagnosis in a child may raise clinical suspicion. Among children with cancer, the shingles rate is dramatically elevated compared to their healthy peers. The nationwide cohort study cited earlier found that the overall rate was roughly nine times higher, and for children with leukemia, the increase was about 14-fold.⁴ Teenagers with cancer showed an even steeper relative risk than younger children, possibly because adolescents’ immune systems respond differently to the combined burden of cancer and its treatment.

For parents of children undergoing cancer treatment, shingles is a complication worth knowing about. The pain and skin damage from a shingles episode can be particularly distressing for young patients already dealing with the side effects of chemotherapy. Prompt recognition of the characteristic one-sided, blistering rash and early antiviral treatment can shorten the illness and reduce the risk of lasting nerve pain. Vaccination strategies for pediatric cancer patients are more complex than for adults and depend on the child’s treatment status and immune function, so these decisions are best handled by the treating oncology team.

The Practical Picture for Patients

If you have been diagnosed with cancer, your risk of shingles is elevated to varying degrees depending on the type of cancer you have and the treatments you receive. Blood cancers and immunosuppressive therapies carry the highest risk. Practical steps that reduce your chances include getting the recombinant zoster vaccine if your oncologist considers the timing appropriate, taking daily antiviral prophylaxis if your treatment regimen calls for it, and knowing the early signs of shingles so you can start treatment quickly. If you develop shingles and have no known reason for immune suppression, there is a statistically small but real chance it reflects an early immune disruption from an undiagnosed cancer, though the absolute risk is low enough that routine cancer screening based solely on a shingles diagnosis is not currently recommended.¹⁵ Staying up to date on standard cancer screenings remains the most practical approach.

1
British Journal of Cancer. Herpes zoster risk after 21 specific cancers: population-based case–control study
2
PubMed Central. Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients
3
PubMed. Postherpetic neuralgia in the cancer patient
4
PubMed Central. Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study
5
PubMed Central. Herpes Zoster Risk Among US Cancer Patients Following Initiation of Immunosuppressive Therapy
6
PubMed. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy
7
PubMed. Antiviral prophylaxis against herpesviruses (herpes simplex virus, varicella-zoster virus and cytomegalovirus) among patients with cancer
8
PubMed. Herpes zoster and radiation therapy: what radiation oncologists need to know about diagnosing, preventing, and treating herpes zoster
9
PubMed. Radiation therapy and the risk of herpes zoster in patients with cancer
10
Applied Radiation Oncology. Shingles After a Single Fraction of Radiation for Ewing Sarcoma
11
PubMed Central. Radiotherapy Increases the Incidence of Herpes Zoster in Oral Cavity Cancer Patients – a National Population-based Cohort Study
12
PubMed Central. The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study
13
PubMed Central. Herpes zoster as a marker of underlying malignancy
14
PubMed. Herpes Zoster as a Marker of Occult Malignancy in Older Adults: A Real-World Cohort Study
15
PubMed. Herpes zoster as a marker of occult cancer: A systematic review and meta-analysis
16
PubMed Central. Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations
17
PubMed Central. Enhancing Herpes Zoster Vaccination Rates Among Oncology Outpatients: Impact of an In-House Vaccination Initiative
18
PubMed Central. A case of cutaneous metastasis mimicking herpes zoster rash
19
CHEST. Zosteriform Skin Metastasis of Lung Cancer